BR9814415A - "método para desenvolver, testar e utilizar associados de macromoléculas e agregados de complexos para carga útil aumentada e velocidades de desassociação controláveis" - Google Patents

"método para desenvolver, testar e utilizar associados de macromoléculas e agregados de complexos para carga útil aumentada e velocidades de desassociação controláveis"

Info

Publication number
BR9814415A
BR9814415A BR9814415-4A BR9814415A BR9814415A BR 9814415 A BR9814415 A BR 9814415A BR 9814415 A BR9814415 A BR 9814415A BR 9814415 A BR9814415 A BR 9814415A
Authority
BR
Brazil
Prior art keywords
aggregates
testing
associates
charged
macromolecule
Prior art date
Application number
BR9814415-4A
Other languages
English (en)
Inventor
Gregor Cevc
Original Assignee
Idea Innovat Dermale Appl Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idea Innovat Dermale Appl Gmbh filed Critical Idea Innovat Dermale Appl Gmbh
Publication of BR9814415A publication Critical patent/BR9814415A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dispersion Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Manufacture Of Macromolecular Shaped Articles (AREA)

Abstract

Patente de Invenção: <B>"MéTODO PARA DESENVOLVER, TESTAR E UTILIZAR ASSOCIADOS DE MACROMOLéCULAS E AGREGADOS DE COMPLEXOS PARA CARGA úTIL AUMENTADA E VELOCIDADES DE DESASSOCIAçãO CONTROLáVEIS"<D>. A invenção descreve os princípios e os procedimentos adequados para o desenvolvimento, teste, fabricação e utilização de combinações de diversas macromoléculas anfipáticas, se necessário modificadas (tais como polipeptídios, proteínas, etc.) ou outras moléculas de cadeia (tais como adequadas, por exemplo, polinucleotídeos ou polissacarídeos parcialmente tornados hidrófobos) com agregados que compreende uma mistura de anfipatos polares e ou carregados e formam superfícies prolongadas que podem ser livremente suspensas ou sustentadas. Os métodos descritos podem ser utilizados para a otimização de agregados que, depois da associação com moléculas de cadeia que exercem alguma atividade ou uma função útil, são adequados para a aplicação in vitro ou in vivo, por exemplo, nos campos de transferência de drogas, diagnósticos ou catálise biológica. Como exemplos especiais, são descritas misturas de gotículas vesiculares que consistem em lipídios carregados (associados) com insulina, interferon, interleucina, fator de crescimento de nervo, calcitonina e uma imunoglobulina, etc.
BR9814415-4A 1998-10-23 1998-10-23 "método para desenvolver, testar e utilizar associados de macromoléculas e agregados de complexos para carga útil aumentada e velocidades de desassociação controláveis" BR9814415A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP1998/006750 WO2000024377A1 (en) 1998-10-23 1998-10-23 Method for developing, testing and using associates of macromolecules and complex aggregates for improved payload and controllable de/association rates

Publications (1)

Publication Number Publication Date
BR9814415A true BR9814415A (pt) 2000-10-10

Family

ID=8167110

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9814415-4A BR9814415A (pt) 1998-10-23 1998-10-23 "método para desenvolver, testar e utilizar associados de macromoléculas e agregados de complexos para carga útil aumentada e velocidades de desassociação controláveis"

Country Status (13)

Country Link
US (2) US20080311184A1 (pt)
EP (1) EP1039880A1 (pt)
JP (1) JP4838936B2 (pt)
KR (1) KR100464601B1 (pt)
CN (1) CN1192766C (pt)
AU (1) AU765385C (pt)
BR (1) BR9814415A (pt)
CA (1) CA2309633C (pt)
HK (1) HK1032745A1 (pt)
HU (1) HUP0102741A3 (pt)
MX (1) MXPA00006196A (pt)
NO (1) NO20003287L (pt)
WO (1) WO2000024377A1 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1031347T1 (en) 1999-01-27 2002-10-31 Idea Ag Transnasal transport/immunisation with highly adaptable carriers
DK1031346T3 (da) 1999-01-27 2002-08-12 Idea Ag Ikke-invasiv vaccination gennem huden
US20040105881A1 (en) * 2002-10-11 2004-06-03 Gregor Cevc Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin
GB2398495B (en) * 2003-01-23 2007-08-22 Kent G Lau A drug delivery preparation comprising at least one anti-tumour drug and a topical carrier for the drug
UA75030C2 (en) * 2005-11-30 2006-03-15 Viktor Oleksandrovych Bykov Method for obtaining stable aqueous solutions of drugs
GB0623838D0 (en) * 2006-11-29 2007-01-10 Malvern Cosmeceutics Ltd Novel compositions
US8962015B2 (en) 2007-09-28 2015-02-24 Sdg, Inc. Orally bioavailable lipid-based constructs
JP6051157B2 (ja) 2010-07-14 2016-12-27 中国医学科学院▲薬▼物研究所 一種インスリンの脂質複合物及び作製方法や製剤
US8422540B1 (en) 2012-06-21 2013-04-16 CBF Networks, Inc. Intelligent backhaul radio with zero division duplexing
KR101849441B1 (ko) 2015-03-19 2018-04-16 김태구 캔 오프너
KR20160112915A (ko) 2015-10-23 2016-09-28 김태구 캔 오프너
WO2017087685A1 (en) * 2015-11-20 2017-05-26 The Regents Of The University Of California Deformable nano-scale vehicles (dnvs) for trans-blood brain barrier, trans-mucosal, and transdermal drug delivery
SG11201908052PA (en) * 2017-03-13 2019-09-27 Sdg Inc Lipid-based nanoparticles with enhanced stability
AU2018331357A1 (en) 2017-09-18 2020-04-02 Bayer Healthcare Llc Methods of inactivation of viruses using N-methylglucamides and its Derivatives
US20220030860A1 (en) * 2018-08-08 2022-02-03 3M Innovative Properties Company Therapeutic composition and related methods
KR20220118210A (ko) * 2021-02-18 2022-08-25 (주)아모레퍼시픽 트랜스퍼좀을 포함하는 난용성 효능물질 전달체
CN115350330B (zh) * 2022-09-01 2023-10-20 北京化工大学 一种负电性小分子调控的表面在蛋白差异性黏附上的应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL64397A0 (en) * 1981-01-07 1982-02-28 Weder Hans G Process for the preparation of liposomal medicaments
US5008050A (en) * 1984-06-20 1991-04-16 The Liposome Company, Inc. Extrusion technique for producing unilamellar vesicles
US4897269A (en) * 1984-09-24 1990-01-30 Mezei Associates Limited Administration of drugs with multiphase liposomal delivery system
US4937182A (en) * 1985-12-19 1990-06-26 Peralta Cancer Research Institute Method for predicting chemosensitivity of anti-cancer drugs
US5244678A (en) * 1986-01-14 1993-09-14 Ire-Celltarg S.A. Pharmaceutical composition containing a local anesthetic and/or centrally acting analgesic encapsulated in liposomes
CA1308025C (en) * 1986-11-28 1992-09-29 Paul A. Tremblay Phospholipid composition
US4849224A (en) * 1987-11-12 1989-07-18 Theratech Inc. Device for administering an active agent to the skin or mucosa
US5043165A (en) * 1988-12-14 1991-08-27 Liposome Technology, Inc. Novel liposome composition for sustained release of steroidal drugs
US5049392A (en) * 1989-01-18 1991-09-17 The Liposome Company, Inc. Osmotically dependent vesicles
DE68912763T2 (de) * 1989-02-24 1994-08-18 Agfa Gevaert Nv Farbstoffdonorelement für die thermische Farbstoffsublimationsübertragung.
US5580575A (en) * 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
JP3765579B2 (ja) * 1990-08-24 2006-04-12 イーデーエーアー アーゲー 作用物質投与用超微小滴状調剤
US5202125A (en) * 1990-12-10 1993-04-13 Theratech, Inc. Method and systems for administering nitroglycerin transdermally at enhanced transdermal fluxes
JP2922017B2 (ja) * 1991-03-25 1999-07-19 第一製薬株式会社 経口用脂質膜構造体
US5498420A (en) * 1991-04-12 1996-03-12 Merz & Co. Gmbh & Co. Stable small particle liposome preparations, their production and use in topical cosmetic, and pharmaceutical compositions
HU223343B1 (hu) * 1991-05-20 2004-06-28 Novartis Ag. Allil-amin-származékot tartalmazó gyógyászati készítmények és eljárás azok előállítására
GB9116610D0 (en) * 1991-08-01 1991-09-18 Danbiosyst Uk Preparation of microparticles
EG20380A (en) * 1991-10-16 1999-02-28 Richardson Vicks Inc Enhanced skin penetration system for improved topical delivery of drugs
ATE162725T1 (de) * 1991-10-16 1998-02-15 Richardson Vicks Inc Verbesserte hautpenetrationssysteme fuer erhoehte topische freisetzung von arzneimitteln
WO1994001089A1 (de) * 1992-07-08 1994-01-20 Dianorm-Geräte G. Maierhofer Liposomen, verfahren zu ihrer herstellung und ihre verwendung zur herstellung eines arzneimittels
BR9306816A (pt) * 1992-07-28 1998-12-08 Procter & Gamble Composição farmaceutica para uso tópico contendo um polímero catiônico reticulado e um eter alcoxilado
US5460820B1 (en) * 1993-08-03 1999-08-03 Theratech Inc Method for providing testosterone and optionally estrogen replacement therapy to women
AU3559695A (en) * 1994-09-30 1996-04-26 Inex Pharmaceuticals Corp. Glycosylated protein-liposome conjugates and methods for their preparation
EP0716559B1 (en) * 1994-12-07 2004-03-03 Tokyo Cosmos Electric Co., Ltd. Planar heating device for use with mirrors
DE4447287C1 (de) * 1994-12-30 1996-11-07 Cevc Gregor Präparat zum Wirkstofftransport durch Barrieren
US5654337A (en) * 1995-03-24 1997-08-05 II William Scott Snyder Topical formulation for local delivery of a pharmaceutically active agent
US5783208A (en) * 1996-07-19 1998-07-21 Theratech, Inc. Transdermal drug delivery matrix for coadministering estradiol and another steroid
US5891472A (en) * 1996-11-19 1999-04-06 Meri Charmyne Russell Treatment of equine laminitis
US5891467A (en) * 1997-01-31 1999-04-06 Depotech Corporation Method for utilizing neutral lipids to modify in vivo release from multivesicular liposomes
US6726925B1 (en) * 1998-06-18 2004-04-27 Duke University Temperature-sensitive liposomal formulation
CN1320880C (zh) * 1998-12-23 2007-06-13 伊迪亚股份公司 改进的体内局部无创伤用制剂
AU5409699A (en) * 1999-07-05 2001-01-22 Idea Ag A method for the improvement of transport across adaptable semi-permeable barriers
US6562370B2 (en) * 1999-12-16 2003-05-13 Dermatrends, Inc. Transdermal administration of steroid drugs using hydroxide-releasing agents as permeation enhancers
JP2002063747A (ja) * 2000-08-18 2002-02-28 Sony Corp 記録媒体および記録媒体原盤ならびに記録媒体の製造方法
US20040105881A1 (en) * 2002-10-11 2004-06-03 Gregor Cevc Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin
GB0417494D0 (en) * 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine

Also Published As

Publication number Publication date
CN1192766C (zh) 2005-03-16
KR100464601B1 (ko) 2004-12-31
HUP0102741A3 (en) 2002-12-28
NO20003287D0 (no) 2000-06-22
HUP0102741A2 (hu) 2002-03-28
AU1435099A (en) 2000-05-15
AU765385B2 (en) 2003-09-18
JP2002528406A (ja) 2002-09-03
US20080311184A1 (en) 2008-12-18
HK1032745A1 (en) 2001-08-03
KR20010033518A (ko) 2001-04-25
AU765385C (en) 2004-05-20
NO20003287L (no) 2000-08-23
EP1039880A1 (en) 2000-10-04
WO2000024377A1 (en) 2000-05-04
CA2309633A1 (en) 2000-05-04
US20080279815A1 (en) 2008-11-13
CA2309633C (en) 2010-12-14
CN1283107A (zh) 2001-02-07
JP4838936B2 (ja) 2011-12-14
MXPA00006196A (es) 2003-07-21

Similar Documents

Publication Publication Date Title
BR9814415A (pt) &#34;método para desenvolver, testar e utilizar associados de macromoléculas e agregados de complexos para carga útil aumentada e velocidades de desassociação controláveis&#34;
Erbayraktar et al. Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo
Scorgie et al. Stress and coping in families of children with disabilities: An examination of recent literature.
DE60009533T2 (de) Multiple analyse von zytokinen
ATE298253T1 (de) In vivo gentransfermethoden zur wundheilung
NZ323795A (en) Isolated nucleic acid molecules encoding AUR-1 (aurora-1) and AUR-2 polypeptides
BR0211614A (pt) polipeptìdeo tacis e br3 e empregos dos mesmos
BR9507505A (pt) Molécula de dna isolada vetor de expressão recombinante célula hospedeira método para preparar um polipeptídeo que estimula uma resposta imunológica th1 em células mononucleares do sangue periférico obtidas a partir de um individuo infectado com leishmania polipeptídeo método para avaliar a capacidade de um paciente de gerar uma resposta imunológica método para melhorar uma resposta imunológica celular e/ou humoral a um antígeno de um paciente método para estimular a produção de anticorpos em um
WO2000015790A3 (en) Leptin induced genes
Brown et al. Modulation of in vitro erythropoiesis: enhancement of erythroid colony growth by cyclic nucleotides
Zhu et al. Synthesis of novel S-neoglycopeptides from glycosylthiomethyl derivatives
PT92403A (pt) Processo para a preparacao de glicoesfingolipidos com grupos susceptiveis de aclopamento na fraccao esfingoide e de composicoes farmaceuticas que os contem
BRPI0409476A (pt) uso de b7-h3 como um agente imunorregulador
Yoo et al. A rapid crosslinkable maleimide-modified hyaluronic acid and gelatin hydrogel delivery system for regenerative applications
DE4221836A1 (de) Das biochemisch aufgereinigte Mistel-Lektin (ML-1) als therapeutisch anwendbarer Immunmodulator
Durand et al. In vivo hypobaric hypoxia performed during the remodeling process accelerates bone healing in mice
Vincenzi et al. Plasma membrane calcium transport and membrane-bound enzymes
Järvinen et al. Macromolecular composition of the myotendinous junction
DE69927669D1 (de) Für reduzierende bedingungen empfindliche transfektions-verbindungen, pharmazeutische zusammensezungen die diese enthalten und deren verwendung.
ES2023631T3 (es) Ensayo de fagocitosis.
CU22737A1 (es) Proteínas de fusión recombinantes basadas en adhesinas bacterianas para el desarrollo de ensayos diagnóstico
El Hamoui et al. Nucleoside-Derived Low-Molecular-Weight Gelators as a Synthetic Microenvironment for 3D Cell Culture
Rogers McCance & Huether’s Pathophysiology-E-Book: The Biologic Basis for Disease in Adults and Children
Weisenberg et al. Microtubule gelation‐contraction in vitro and its relationship to component a of slow axonal transport
Sickles et al. Are fast glycolytic fibers present in slow loris (Nycticebus coucang) hindlimb muscles?

Legal Events

Date Code Title Description
TC Change of name
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: DE ACORDO COM O ART. 37, INDEFIRO DO PRESENTE PEDIDO, UMA VEZ QUE: NAO ATENDE AO REQUISITO DE NOVIDADE ( ART. 8O COMBINADO COM O ART. 11 DA LPI 9279/96); AS REIVINDICACOES ESTAO INDEFINIDAS E/OU NAO ESTAO FUNDAMENTADAS NO RELATORIO DESCRITIVO (ART. 25 DA LPI).

B12B Appeal against refusal [chapter 12.2 patent gazette]